AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11851638 — intervention group
Group type: EXPERIMENTAL
Intervention: S 18326 (3 mg h‐1)
Number of subjects: 36
Study 11851638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10703776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tPA (recombinant alteplase)
Number of subjects: 389
Study 8963728 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 220
Study 8963728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 1350562 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg initially and 1 mg every 4 hr for 24 hr)
Number of subjects: 33
Study 1350562 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin (250 micrograms as a bolus and continuous infusion of 250 micrograms/hr for 24 hr)
Number of subjects: 33
Study 1350562 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 33
Study 1350562 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin
Number of subjects: 33
Study 1350562 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin and Somatostatin (both groups)
Number of subjects: 33
Study 2578707 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg acyclovir four times a day for 12 weeks
Number of subjects: 31
Study 2578707 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo four times a day for 12 weeks
Number of subjects: 31
Study 30477000 — intervention group
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec plus ipilimumab
Number of subjects: 198
Study 27717153 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental Shuttle Walk Test (ISWT)
Number of subjects: 128
Study 27717153 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA) using 3 MET threshold
Number of subjects: 128
Study 27717153 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA) using individually prescribed MET threshold
Number of subjects: 128
Study 27422599 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Hz group - exercise protocol with the platform on
Number of subjects: 60
Study 27422599 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Hz group - exercise protocol with the platform on
Number of subjects: 60
Study 27422599 — intervention group
Group type: COMPARATOR
Intervention: Control group - exercise protocol with the platform off
Number of subjects: 60
Study 24824197 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg once daily
Number of subjects: 272
Study 24824197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 23134891 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine (750 mg)
Number of subjects: 140
Study 23134891 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 140
Study 20729686 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealing for mesh fixation
Number of subjects: 12
Study 20729686 — intervention group
Group type: COMPARATOR
Intervention: Mechanical stapling (control)
Number of subjects: 12
Study 18823461 — intervention group
Group type: EXPERIMENTAL
Intervention: 660 mg of aspirin
Number of subjects: 34
Study 18823461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 16084069 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose estrogen replacement therapy (ultralow dose micronized estradiol)
Number of subjects: 16
Study 12190127 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy-assisted transoral approach
Number of subjects: 17
Study 12190127 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy-assisted submandibular approach
Number of subjects: 17
Study 12190127 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy-assisted treatment with angulated drills and screwdrivers
Number of subjects: 17
Study 12190127 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraoral approach
Number of subjects: 17
Study 10487502 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 34
Study 10487502 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic capillaroscopy in obese children
Number of subjects: 34
Study 10487502 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma lipids examination in obese children
Number of subjects: 34
Study 10487502 — intervention group
Group type: EXPERIMENTAL
Intervention: Pearson analysis in obese children
Number of subjects: 34
Study 10487502 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment in obese children
Number of subjects: 34
Study 10487502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutaneous microcirculatory assessment in obese children
Number of subjects: 34
Study 8598593 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention schools (CATCH intervention)
Number of subjects: 5106
Study 8598593 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 5106
Study 30328294 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (14,000 U weekly for 8 months)
Number of subjects: 1300
Study 30328294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1300
Study 29121975 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 cup of espresso coffee/day
Number of subjects: 21
Study 29121975 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cups of espresso coffee/day
Number of subjects: 21
Study 29121975 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 cup of espresso coffee plus 2 cocoa-based products containing coffee twice per day
Number of subjects: 21
Study 25557658 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8mg/kg + methotrexate (MTX) every 4 weeks for 48 weeks
Number of subjects: 103
Study 23823946 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 0
Study 23823946 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 0
Study 21059662 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm sling
Number of subjects: 37
Study 18679151 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (2 mg/kg)
Number of subjects: 106
Study 18679151 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B (3 mg/kg)
Number of subjects: 106
Study 18679151 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin
Number of subjects: 106
Study 18679151 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B
Number of subjects: 106
Study 15583955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin 50 mL/day for 21 days
Number of subjects: 146
Study 15583955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 12853587 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (dalteparin) at a dose of 200 IU per kilogram subcutaneously once daily for five to seven days and a coumarin derivative for six months (target INR 2.5)
Number of subjects: 336
Study 12853587 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulant (coumarin derivative)
Number of subjects: 336
Study 12853587 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (dalteparin)
Number of subjects: 336
Study 10725819 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg
Number of subjects: 61
Study 10725819 — intervention group
Group type: COMPARATOR
Intervention: Loratadine 10 mg
Number of subjects: 61
Study 8967154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba special extract EGb 761 (3 times 1 film-coated tablet of 40 mg per day)
Number of subjects: 60
Study 8967154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8967154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba special extract EGb 761
Number of subjects: 60
Study 1737539 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose insulin regimen (15% regular, 85% NPH) given before breakfast and dinner
Number of subjects: 10
Study 1737539 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-dose insulin regimen (regular insulin before meals and NPH at 2200)
Number of subjects: 10
Study 1737539 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (nondiabetic)
Number of subjects: 10
Study 6202098 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg propranolol (Inderal)
Number of subjects: 14
Study 6202098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31486833 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR-TKIs plus metformin (500 mg twice a day)
Number of subjects: 139
Study 31486833 — intervention group
Group type: COMPARATOR
Intervention: EGFR-TKIs alone
Number of subjects: 139
Study 29174665 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to tobacco advertisements
Number of subjects: 56
Study 29174665 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to menthol advertisements
Number of subjects: 56
Study 29174665 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher advertisement exposure
Number of subjects: 56
Study 29174665 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased advertisement exposure (within-subject analysis)
Number of subjects: 56
Study 29174665 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent time period after increased advertisement exposure
Number of subjects: 56
Study 26359341 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Story Memory Technique (mSMT)
Number of subjects: 69
Study 24938504 — intervention group
Group type: EXPERIMENTAL
Intervention: Network treatment (intervention group)
Number of subjects: 235
Study 24938504 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 235
Study 22252217 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg 3 times/week
Number of subjects: 120
Study 22252217 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 120
Study 22252217 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 120
Study 20846257 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 600 microg misoprostol
Number of subjects: 64
Study 20846257 — intervention group
Group type: COMPARATOR
Intervention: Sublingual 600 microg misoprostol
Number of subjects: 64
Study 19092248 — intervention group
Group type: EXPERIMENTAL
Intervention: CR oxycodone plus pregabalin
Number of subjects: 409
Study 19092248 — intervention group
Group type: EXPERIMENTAL
Intervention: CR oxycodone
Number of subjects: 409
Study 19092248 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 409
Study 15903381 — intervention group
Group type: EXPERIMENTAL
Intervention: Overhead goal
Number of subjects: 35
Study 15903381 — intervention group
Group type: COMPARATOR
Intervention: No overhead goal
Number of subjects: 35
Study 12915604 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IV IL-2 (720,000 U/kg)
Number of subjects: 400
Study 12915604 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IV IL-2 (72,000 U/kg)
Number of subjects: 400
Study 12915604 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose daily subcutaneous IL-2
Number of subjects: 400
Study 10485635 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (75 or 150 mg/day)
Number of subjects: 365
Study 10485635 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (30 mg/day in 3 divided doses)
Number of subjects: 365
Study 10485635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study 8738759 — intervention group
Group type: EXPERIMENTAL
Intervention: R-methadone (tablets)
Number of subjects: 10
Study 8738759 — intervention group
Group type: EXPERIMENTAL
Intervention: S-methadone (tablets)
Number of subjects: 10
Study 2016246 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy for 3 or 6 weeks
Number of subjects: 34
Study 2016246 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 34
Study 2016246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 2016246 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy (6 weeks vs. 3 weeks)
Number of subjects: 34
Study 2016246 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy homework compliance
Number of subjects: 34
Study 2016246 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial severity of illness
Number of subjects: 34
Study 2016246 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression levels
Number of subjects: 34
Study 2016246 — intervention group
Group type: EXPERIMENTAL
Intervention: General anxiety levels
Number of subjects: 34
Study 7127999 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release furosemide (FR, 60 mg)
Number of subjects: 12
Study 7127999 — intervention group
Group type: COMPARATOR
Intervention: Conventional furosemide tablet (F, 40 mg)
Number of subjects: 12
Study 29743136 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic strengthening plus family coaching component (TU + arm)
Number of subjects: 360
Study 29743136 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic intervention utilizing the Graduation approach (Trickle Up/TU arm)
Number of subjects: 360
Study 26729582 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA + AZA (n = 53)
Number of subjects: 204
Study 26729582 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA + MMF (n = 53)
Number of subjects: 204
Study 26729582 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA monotherapy (n = 98)
Number of subjects: 204
Study 26729582 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA + AZA
Number of subjects: 204
Study 26729582 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA + MMF
Number of subjects: 204
Study 26729582 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA monotherapy
Number of subjects: 204
Study 26729582 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole cohort
Number of subjects: 204
Study 26729582 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 204
Study 26729582 — intervention group
Group type: EXPERIMENTAL
Intervention: AZA
Number of subjects: 204
Study 26729582 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF
Number of subjects: 204
Study 26729582 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA
Number of subjects: 204
Study 25304142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic bone surgery
Number of subjects: 200
Study 25304142 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgery
Number of subjects: 200
Study 21927844 — intervention group
Group type: EXPERIMENTAL
Intervention: GFLX-containing regimen (gatifloxacin)
Number of subjects: 27
Study 21927844 — intervention group
Group type: COMPARATOR
Intervention: CAM-containing regimen (clarithromycin)
Number of subjects: 27
Study 20127127 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral intervention
Number of subjects: 31
Study 20127127 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 31
Study 18396071 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoropassiv patch
Number of subjects: 87
Study 18396071 — intervention group
Group type: COMPARATOR
Intervention: Venous patch
Number of subjects: 87
Study 15632665 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype carbohydrate‐electrolyte drink (PCE)
Number of subjects: 19
Study 15632665 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available carbohydrate‐electrolyte drink (CCE)
Number of subjects: 19
Study 15632665 — intervention group
Group type: COMPARATOR
Intervention: Water (neutral control)
Number of subjects: 19
Study 12873261 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 400 mg
Number of subjects: 272
Study 12873261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 10925929 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (20 g) applied perioperatively and daily for 4 days post-surgery
Number of subjects: 46
Study 10925929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 8677990 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine suspension enema (4 g at night)
Number of subjects: 37
Study 8677990 — intervention group
Group type: COMPARATOR
Intervention: Oral sulfasalazine (1 g four times a day)
Number of subjects: 37
Study 1986150 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy group - three monthly doses of 500 micrograms of TAA emulsified with CFA
Number of subjects: 85
Study 1986150 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific immunotherapy group - three monthly doses of CFA emulsified in saline
Number of subjects: 85
Study 1986150 — intervention group
Group type: COMPARATOR
Intervention: Control group - no treatment
Number of subjects: 85
Study 6653642 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (P) therapy
Number of subjects: 13
Study 30637907 — intervention group
Group type: EXPERIMENTAL
Intervention: 1Hz MSCS
Number of subjects: 15
Study 30637907 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study 30232949 — intervention group
Group type: EXPERIMENTAL
Intervention: Active devices that applied moisture to the external ear
Number of subjects: 8
Study 30232949 — intervention group
Group type: COMPARATOR
Intervention: Placebo devices that contained no moisture
Number of subjects: 8
Study 28178109 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk reduction counseling and condoms provided throughout the trial
Number of subjects: 4843
Study 26519909 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal reminders for vaccination
Number of subjects: 0
Study 23153388 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis treatment (5 sessions over 2 months)
Number of subjects: 59
Study 23153388 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 59
Study 21516330 — intervention group
Group type: COMPARATOR
Intervention: Arm cycling at 1 Hz with contralateral arm at rest
Number of subjects: 12
Study 21516330 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm cycling at 1 Hz with contralateral arm cycling at 1 Hz
Number of subjects: 12
Study 21516330 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm cycling at 1 Hz with contralateral arm cycling at 2 Hz
Number of subjects: 12
Study 18285645 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing aid (Aid)
Number of subjects: 12
Study 18285645 — intervention group
Group type: COMPARATOR
Intervention: No aid (No aid)
Number of subjects: 12
Study 17163277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 40mg
Number of subjects: 218
Study 17163277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 80mg
Number of subjects: 218
Study 17163277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 160mg
Number of subjects: 218
Study 17163277 — intervention group
Group type: EXPERIMENTAL
Intervention: Average dose of Ziprasidone
Number of subjects: 218
Study 17163277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 14723254 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 54
Study 14723254 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime plus amikacin
Number of subjects: 54
Study 14723254 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 54
Study 11034035 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamulus fracture during palatoplasty (85 patients)
Number of subjects: 173
Study 11034035 — intervention group
Group type: COMPARATOR
Intervention: No hamulus fracture during palatoplasty (76 patients)
Number of subjects: 173
Study 9378833 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer toothpaste
Number of subjects: 143
Study 9378833 — intervention group
Group type: COMPARATOR
Intervention: Stannous fluoride toothpaste
Number of subjects: 143
Study 9378833 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoride toothpaste
Number of subjects: 143
Study 9378833 — intervention group
Group type: COMPARATOR
Intervention: Triclosan/zinc citrate toothpaste
Number of subjects: 143
Study 8466062 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 1.0 mg
Number of subjects: 12
Study 8466062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3541946 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate inhaled as a dry-powder, 400 micrograms twice daily
Number of subjects: 16
Study 3541946 — intervention group
Group type: COMPARATOR
Intervention: Conventional aerosol, 100 micrograms four times daily
Number of subjects: 16
Study 29683755 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg orally twice daily from day 0 to 5
Number of subjects: 70
Study 29683755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 26558724 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-B vaccine
Number of subjects: 21
Study 26558724 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 27687887 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt-reduction and efficacy-maintenance program
Number of subjects: 51
Study 27687887 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt-reduction training
Number of subjects: 51
Study 27687887 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 22748952 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation thermal uterine balloon therapy (UBT) system with no post-procedure curettage (PPC)
Number of subjects: 250
Study 22748952 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation thermal uterine balloon therapy (UBT) system with post-procedure curettage (PPC)
Number of subjects: 250
Study 22748952 — intervention group
Group type: COMPARATOR
Intervention: First-generation UBT system
Number of subjects: 250
Study 19570664 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calorie (LF-LC) (-2MJ)
Number of subjects: 150
Study 19570664 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calorie with 10% polyunsaturated fatty acids (LF-PUFA-LC)
Number of subjects: 150
Study 19570664 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric with 10% polyunsaturated fatty acids (LF-PUFA)
Number of subjects: 150